Complete Removal of Extracellular IgG Antibodies in a Randomized Dose-Escalation Phase I Study With the Bacterial Enzyme IdeS – A Novel Therapeutic Opportunity

PLoS ONE - United States
doi 10.1371/journal.pone.0132011
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Public Library of Science (PLoS)

Related search

A Phase I Dose-Escalation Study of Intravenous Panobinostat in Patients With Lymphoma and Solid Tumors

Investigational New Drugs
OncologyPharmacology
2013English

A Phase I Dose-Escalation Study of a Biosimilar Trastuzumab in Chinese Metastasis Breast Cancer Patients

SpringerPlus
Multidisciplinary
2015English

A Phase I/Ii Seamless Dose Escalation/Expansion With Adaptive Randomization Scheme (SEARS)

Clinical Trials
MedicinePharmacology
2013English

A Phase I Dose-Escalation Study of Selumetinib in Combination With Docetaxel or Dacarbazine in Patients With Advanced Solid Tumors

BMC Cancer
Cancer ResearchOncologyGenetics
2017English

Human Amnion Cells for the Prevention of Bronchopulmonary Dysplasia: A Protocol for a Phase I Dose Escalation Study

BMJ Open
Medicine
2019English

A Phase I Dose-Escalation and Pharmacokinetic Study of Brostallicin (PNU-166196A), a Novel DNA Minor Groove Binder, in Adult Patients With Advanced Solid Tumors

Clinical Cancer Research
Cancer ResearchOncology
2004English

A Phase I Dose-Escalation Study of IMAB362 (Zolbetuximab) in Patients With Advanced Gastric and Gastro-Oesophageal Junction Cancer

European Journal of Cancer
Cancer ResearchOncology
2018English

A Phase I Dose‐Escalation Study of the Safety and Pharmacokinetics of Pictilisib in Combination With Erlotinib in Patients With Advanced Solid Tumors

Oncologist
Cancer ResearchMedicineOncology
2017English

Phase I Dose-Escalation Study and Biomarker Analysis of E7080 in Patients With Advanced Solid Tumors

Clinical Cancer Research
Cancer ResearchOncology
2011English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy